TR200201613T2 - Antitümör tesirli 2-(1H-indol-3-il)-2-okso asetamidler - Google Patents

Antitümör tesirli 2-(1H-indol-3-il)-2-okso asetamidler

Info

Publication number
TR200201613T2
TR200201613T2 TR2002/01613T TR200201613T TR200201613T2 TR 200201613 T2 TR200201613 T2 TR 200201613T2 TR 2002/01613 T TR2002/01613 T TR 2002/01613T TR 200201613 T TR200201613 T TR 200201613T TR 200201613 T2 TR200201613 T2 TR 200201613T2
Authority
TR
Turkey
Prior art keywords
acetamides
indol
oxo
antitumor effect
tumors
Prior art date
Application number
TR2002/01613T
Other languages
English (en)
Inventor
Menta Ernesto
Pescalli Nicoletta
Original Assignee
Novuspharma S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novuspharma S.P.A. filed Critical Novuspharma S.P.A.
Publication of TR200201613T2 publication Critical patent/TR200201613T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Yukaridaki formül (I)'in özellikle sert tümörler, daha ayrintili olarak da bagirsak ve akciger tümörleri karsisinda antitümör tesiri sergileyen 2-(1H-indol-3-il)-2-okso-asetamidleri olup, bu formüldeki Y oksijen veya sülfür atomu ve X,R1,R2,R3,R4, ve R5 de istem 1'de tanimlandigi gibidir.
TR2002/01613T 1999-12-23 2000-12-21 Antitümör tesirli 2-(1H-indol-3-il)-2-okso asetamidler TR200201613T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999MI002693A IT1315267B1 (it) 1999-12-23 1999-12-23 Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale

Publications (1)

Publication Number Publication Date
TR200201613T2 true TR200201613T2 (tr) 2002-10-21

Family

ID=11384182

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01613T TR200201613T2 (tr) 1999-12-23 2000-12-21 Antitümör tesirli 2-(1H-indol-3-il)-2-okso asetamidler

Country Status (24)

Country Link
US (1) US6753342B2 (tr)
EP (1) EP1244652B1 (tr)
JP (1) JP2003519140A (tr)
KR (1) KR100795533B1 (tr)
CN (1) CN1250542C (tr)
AT (1) ATE302772T1 (tr)
AU (1) AU776332B2 (tr)
BR (1) BR0016553A (tr)
CA (1) CA2395205A1 (tr)
CZ (1) CZ20022170A3 (tr)
DE (1) DE60022227T2 (tr)
EA (1) EA004925B1 (tr)
ES (1) ES2246918T3 (tr)
HU (1) HUP0203524A3 (tr)
IL (2) IL150329A0 (tr)
IT (1) IT1315267B1 (tr)
MX (1) MXPA02006217A (tr)
NO (1) NO323312B1 (tr)
NZ (1) NZ519689A (tr)
PL (1) PL356541A1 (tr)
SK (1) SK285682B6 (tr)
TR (1) TR200201613T2 (tr)
WO (1) WO2001047916A1 (tr)
ZA (1) ZA200204964B (tr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3842043B2 (ja) 1998-04-28 2006-11-08 エルビオン アクチエンゲゼルシャフト 新規ヒドロキシインドール、ホスホジエステラーゼ４のインヒビタとしてのその使用及びその製法
IT1318641B1 (it) * 2000-07-25 2003-08-27 Novuspharma Spa Ammidi di acidi 2-(1h-indol-3-il)-2-oxo-acetici ad attivita'antitumorale.
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
CA2767092C (en) * 2002-07-09 2013-10-15 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same and methods of use for same
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
ES2345662T3 (es) * 2004-03-11 2010-09-29 Actelion Pharmaceuticals Ltd. Derivados de acido indol-1-il-acetico.
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
RU2451018C2 (ru) 2006-04-07 2012-05-20 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы атф-связывающих кассетных транспортеров
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
JP5406716B2 (ja) * 2006-08-07 2014-02-05 アイアンウッド ファーマシューティカルズ インコーポレイテッド インドール化合物
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX2012012204A (es) 2010-04-22 2012-12-05 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
WO2012135027A2 (en) * 2011-03-25 2012-10-04 The Research Foundation Of State University Of New York Thiolactone antibiotics
AR092857A1 (es) 2012-07-16 2015-05-06 Vertex Pharma Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
ES2957761T3 (es) 2014-04-15 2024-01-25 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
CN115785079B (zh) * 2022-11-28 2024-02-13 沈阳药科大学 4-(1h-吲哚-5-基)氨基呋喃-2(5h)-酮类化合物及其制备和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0841924T3 (da) * 1995-08-02 2003-02-10 Univ Newcastle Ventures Ltd Benzimidazolforbindelser
CO4970714A1 (es) 1997-09-05 2000-11-07 Boehringer Mannheim Gmbh Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h) tiofenonas como agentes antitumorales
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
JP3842043B2 (ja) * 1998-04-28 2006-11-08 エルビオン アクチエンゲゼルシャフト 新規ヒドロキシインドール、ホスホジエステラーゼ４のインヒビタとしてのその使用及びその製法

Also Published As

Publication number Publication date
HUP0203524A2 (hu) 2003-03-28
ZA200204964B (en) 2004-01-29
ES2246918T3 (es) 2006-03-01
KR20020063247A (ko) 2002-08-01
NO323312B1 (no) 2007-03-12
IT1315267B1 (it) 2003-02-03
HUP0203524A3 (en) 2008-01-28
IL150329A0 (en) 2002-12-01
NO20022976L (no) 2002-06-20
BR0016553A (pt) 2002-09-17
EA200200558A1 (ru) 2002-12-26
SK8962002A3 (en) 2002-11-06
ATE302772T1 (de) 2005-09-15
SK285682B6 (sk) 2007-06-07
NZ519689A (en) 2004-02-27
MXPA02006217A (es) 2004-02-26
ITMI992693A1 (it) 2001-06-23
JP2003519140A (ja) 2003-06-17
US20030158153A1 (en) 2003-08-21
DE60022227T2 (de) 2006-06-22
CN1413205A (zh) 2003-04-23
EP1244652B1 (en) 2005-08-24
KR100795533B1 (ko) 2008-01-16
EP1244652A1 (en) 2002-10-02
ITMI992693A0 (it) 1999-12-23
NO20022976D0 (no) 2002-06-20
IL150329A (en) 2006-07-05
US6753342B2 (en) 2004-06-22
CA2395205A1 (en) 2001-07-05
CZ20022170A3 (cs) 2002-09-11
EA004925B1 (ru) 2004-10-28
PL356541A1 (en) 2004-06-28
WO2001047916A1 (en) 2001-07-05
DE60022227D1 (de) 2005-09-29
CN1250542C (zh) 2006-04-12
AU776332B2 (en) 2004-09-02
AU2170401A (en) 2001-07-09

Similar Documents

Publication Publication Date Title
TR200201613T2 (tr) Antitümör tesirli 2-(1H-indol-3-il)-2-okso asetamidler
NL350077I1 (nl) Cyprosulfamide
DE69918422D1 (de) Phthalazinone pde iii/iv hemmer
PT1193270E (pt) Pirrolobenzodiazepinas
ES2152414T3 (es) Dihidrobenzofuranos.
TR199901653T2 (tr) Fitalazinonlar.
DK1200418T3 (da) Nematodicide trifluorbutener
MXPA02010088A (es) Derivados de ecteinascidina antitumorales.
EE200000033A (et) Uudsed tetrasoolderivaadid
DE69821530D1 (de) Dihydrobenzifurane
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
ATE287403T1 (de) 6-phenylbenzonaphthyidine
SE9903290D0 (sv) Novel compounds
ES2178765T3 (es) Nuevos derivados de 1,7,7-trimetil-biciclo (2.2.1) heptano.
BG106937A (en) Novel indole derivatives
DE60136430D1 (de) Heterosubstituierte c7-taxanacetate als antitumormittel
MXPA04000506A (es) Nuevos derivados de et-743 antitumorales.
DE59803066D1 (de) Substituierte benzyloxyimino-verbindungen
TR200003203T2 (tr) Karboksaldehitin saflaştırılması
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine
DE60102695D1 (de) Neue verwendung von citreamicinen
PL373989A1 (en) Novel benzonaphthyridines
UA33865A (uk) Дикалієва сіль n-сукцин - dl-триптофану, що має антиангінальну та антигіпоксантну дію
BR0109394A (pt) Compostos de esponja antitumores